Induced pluripotent stem cells derived from patients carrying mitochondrial mutations exhibit altered bioenergetics and aberrant differentiation potential
Abstract
Human mitochondrial DNA mutations are associated with common to rare mitochondrial disorders, which are multisystemic with complex clinical pathologies. The pathologies of these diseases are poorly understood and have no FDA-approved treatments leading to symptom management. Leigh syndrome (LS) is a pediatric mitochondrial disorder that affects the central nervous system during early development and causes death in infancy. Since there are no adequate models for understanding the rapid fatality associated with LS, human-induced pluripotent stem cell (hiPSC) technology has been recognized as a useful approach to generate patient-specific stem cells for disease modeling and understanding the origins of the phenotype.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 07, 2023
- Source ID
- 10.1186/s13287-023-03546-7
Entities
People
- Bibhuti Saikia
- Christopher M. Littlejohn
- Edward J. Lesnefsky
- Fibi Meshrkey
- Franklin D. West
- Joshua Stabach
- Kelly M. Scheulin
- Raj R. Rao
- Shilpa Iyer
- Thomas Laframboise
- Vedant Thorat
- Yimin Huang
Organizations
- United States Department of Defense